Efficacy, safety, tolerability and immunological effects of Nexvax2®, a peptide-based therapeutic vaccine, administered by intra-dermal (ID) injection twice –weekly for 8 weeks in HLA-DQ2.5+ celiac disease (CeD)

Authors
Publication date
1 January 2016
Publisher
W.B. Saunders

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    University of Queensland eSpace

    redirect
    oaioai:espace.library.uq.edu.au:U...
    Last time updated on 12/10/2017